Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes.

The New England journal of medicine - 1 Dec 2016

Ference Brian A, Robinson Jennifer G, Brook Robert D, Catapano Alberico L, Chapman M John, Neff David R, Voros Szilard, Giugliano Robert P, Davey Smith George, Fazio Sergio, Sabatine Marc S

Abstract excerpt

BACKGROUND: Pharmacologic inhibitors of proprotein convertase subtilisin-kexin type 9 (PCSK9) are being evaluated in clinical trials for the treatment of cardiovascular disease. The effect of lowering low-density lipoprotein (LDL) cholesterol levels by inhibiting PCSK9 on the risk of cardiovascular events or diabetes is unknown. METHODS: We used genetic scores consisting of independently inherited variants in the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cardiovascular Diseases
Share to Cholesterol, LDL

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Diabetes Mellitus

Share to Genetic Variation

Share to Hydroxymethylglutaryl CoA Reductases

Share to Proprotein Convertase 9

Share to Random Allocation

Source

Identifiers

PMID: 27959767
DOI: 10.1056/NEJMoa1604304

Genes

PCSK9
HMGCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes.PMID 27959767Read ↗

PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study.Semantic proximity Read ↗

Genetic Regulation of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Plasma Levels and Its Impact on Atherosclerotic Vascular Disease Phenotypes.Semantic proximity Read ↗

Genetic Assessment of Potential Long-Term On-Target Side Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) InhibitorsSemantic proximity Read ↗

PCSK9 and Lipid Metabolism: Genetic Variants, Current Therapies, and Cardiovascular Outcomes.Semantic proximity Read ↗

Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9.Semantic proximity Read ↗

Meta-GWAS of PCSK9 levels detects two novel loci atAPOBandTM6SF2Semantic proximity Read ↗

PCSK9 loss of function is protective against extra-coronary atherosclerotic cardiovascular disease in a large multi-ethnic cohort.Semantic proximity Read ↗

Multiomic Mendelian Randomization Study Investigating the Impact of PCSK9 and HMGCR Inhibition on Type 2 Diabetes Across Five Populations.Semantic proximity Read ↗

Association Between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and Risk of Type 2 Diabetes: A Meta-analysis.Semantic proximity Read ↗

Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in <i>PCSK9</i>Semantic proximity Read ↗

Genome-wide association of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) plasma levels in the ELSA-Brasil studySemantic proximity Read ↗

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.